If protein aggregates such as tau and α-synuclein could be visualized in the living brain, patients with cognitive symptoms could be classified into AD, DLB, or FTLD, while those with predominant motor symptoms could be differentiated as having PSP, CBD, DLB, PD, or MSA. This evidence concerns the gene MAPT and Lewy body dementia.